Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
NCT00022126
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Bone marrow transplantation allows the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to compare the effectiveness of combination chemotherapy with or without donor bone marrow transplantation in treating infants who have previously untreated acute lymphobla... Read More
Gender:
ALL
Ages:
1 year and below
Trial Updated:
02/18/2014
Locations: Children's Hospital of Denver, Denver, Colorado
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
NCT00002812
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
08/23/2013
Locations: Children's Hospital of Denver, Denver, Colorado
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
NCT00002816
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy in treating children who have relapsed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
20 years and below
Trial Updated:
08/21/2013
Locations: Children's Hospital of Denver, Denver, Colorado
Conditions: Leukemia
Register for Updates
Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients
NCT00507442
Completed
The purpose of this Phase 1/2 study is to evaluate the efficacy and safety of treatment with VELCADE, dexamethasone, and Revlimid® (VDR) as well as VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in patients with multiple myeloma who have received no prior treatment. This study will evaluate whether the addition of Revlimid to VELCADE and Dexamethasone will increase the complete response (CR)/ very good partial response (VGPR) rate.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2013
Locations: Rocky Mountain Cancer Center, Denver, Colorado
Conditions: Multiple Myeloma
Register for Updates
Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma
NCT00000801
Completed
To estimate the response rate, overall and disease-free survival, toxicities, factors associated with outcome, and effect on quality of life in patients with AIDS-related primary CNS lymphoma treated with CHOD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) plus filgrastim (granulocyte-colony stimulating factor; G-CSF) and external beam irradiation. To determine other clinical markers present in this patient population. Combined modality therapy may prove of benefit for patients... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
10/31/2012
Locations: Univ of Colorado Health Sciences Ctr, Denver, Colorado
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
NCT00179647
Completed
Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2010
Locations: University of ColoradoHealth Science Center, Aurora, Colorado +1 locations
Conditions: Multiple Myeloma
Register for Updates